| abstract |
An isolated or synthetic antibody or ligand that specifically binds to an epitope of a dissociating monomer of human tumor necrosis factor (TNF) is provided. Such binding prevents the monomers from aggregating into biologically active trimeric human soluble TNF (sTNF). Further provided is a pharmaceutical composition containing one or more of the isolated antibodies or ligands. Using combinations of antibodies, diseases mediated by human TNF (eg, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis, atherosclerosis, metabolic syndrome, Alzheimer's disease, HIV, II Further disclosed is a method of treating a subject having type 2 diabetes. |